Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10 Metastatic neuroendocrine tumors: Monotherapy data presentations planned. Phase 2 combination therapy trial designs with different classes of checkpoint inhibitor drugs being developed.Metastatic...

Yale Researchers to Present Data at AACR Conference Indicating That Novogen Compound NV-128 Uses mTOR Pathway to Induce Cell Death in Chemo-Resistant Ovarian Cancer Cells SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - March 25, 2008) - An abstract for an oral presentation to be given at the Annual Meeting of the American Association for Cancer Research, April 12...

Phenoxodiol Trials Highlighted at Ovarian Cancer Action International Conference SYDNEY, AUSTRALIA and LONDON and NEW CANAAN, CT--(Marketwire - March 10, 2008) - The role of the investigational drug phenoxodiol in restoration of chemosensitivity in ovarian cancer patients...